Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Completed · Phase 2

Conditions studied: Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia, Myelodysplastic Syndromes

In brief

This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML

Key facts

Study ID
NCT00607997
Run by
Sunesis Pharmaceuticals
People needed
113
Starts
2008-05-15
Expected to finish
2009-11-23
Last updated by the study team
2017-06-28

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.